Not medical advice. Talk to your provider before using any peptide. Full disclaimer
P21
Also known as: P021, P-021
Four amino acids, an adamantane cap, and restored hippocampal neurogenesis in Alzheimer's mice [1]. P21 (also called P021) is a synthetic tetrapeptide carved from residues 148 to 151 of human ciliary neurotrophic factor (CNTF). In mice it works after peripheral dosing; the longest study mixed it into food. The catch: zero human clinical trials exist. Every dosing number comes from rodent models run in Dr. Khalid Iqbal's lab at the New York State Institute for Basic Research. Community users (roughly 30 to 80 Reddit threads) report subtle memory improvements on the intranasal route, but expectations need calibrating to weeks, not days.
What Is P21?
Less tau buildup and restored neurogenesis in triple-transgenic Alzheimer's mice after 12 months of P021 in their diet (Kazim et al. 2014)[1]. Those results put P21 on the nootropic map, despite the compound never entering a single human clinical trial.
P21 (P021, CAS 1246751-68-7) is a synthetic tetrapeptide built from residues 148 to 151 of human CNTF. An adamantylated glycine group caps the C-terminus, protecting it from exopeptidase degradation and allowing it to cross the blood-brain barrier. Full-length CNTF is too large to reach the brain and causes weight loss and antibody formation. P21 was engineered specifically to avoid those problems.
The mechanism works by removing a brake. Leukemia inhibitory factor (LIF) normally suppresses hippocampal neurogenesis through JAK/STAT3 signaling. P21 competitively blocks that suppression, letting neural progenitor cells proliferate. Downstream, BDNF expression rises, TrkB receptors activate, and CREB phosphorylation increases.
Community adoption sits at roughly 30 to 80 Reddit threads across r/nootropics and r/peptides. Most users favor the intranasal route at 500 mcg to 1 mg daily; many report subcutaneous doses below 300 mcg produce no perceivable effect. Reported benefits center on spatial recall and memory consolidation over 3 to 5 weeks. Nobody describes an acute "feel."
A 2024 study in a CDKL5 deficiency disorder model [2] found in vitro benefit but failed to replicate neurogenesis or BDNF improvement in vivo. That result raises questions about generalizability across disease contexts. This compound remains strictly experimental with no established human safety profile.
How P21 Works
Hippocampal neurogenesis in adults runs under tight regulatory control. One of the brakes is leukemia inhibitory factor (LIF), a pleiotropic cytokine that activates the JAK/STAT3 pathway in neural stem cells and keeps them quiescent in the subgranular zone of the dentate gyrus.
P21 competitively inhibits LIF signaling. By blocking that inhibitory input, it releases endogenous neurogenic capacity. Neural progenitor cells that would otherwise sit dormant begin to proliferate and differentiate into mature neurons. The molecular consequences cascade downstream: brain-derived neurotrophic factor (BDNF) expression increases, its high-affinity receptor TrkB activates, and CREB phosphorylation follows. CREB is a master regulator of synaptic plasticity, governing long-term potentiation, dendritic spine formation, and memory consolidation.
P21 also reduces glycogen synthase kinase-3 beta (GSK-3B) activity. Lower GSK-3B means less tau hyperphosphorylation, which is a hallmark of Alzheimer's disease pathology. In 3xTg-AD mice, this translated to a significant drop in hyperphosphorylated tau [1].
The adamantylated glycine modification on the C-terminus does double duty. It resists enzymatic breakdown by exopeptidases. It also provides enough lipophilicity to cross the blood-brain barrier after peripheral administration. That structural trick is what separates P21 from full-length CNTF, which cannot reach the brain from systemic circulation.
All of this is rodent data. No human pharmacodynamic study has confirmed these pathways activate the same way in the human hippocampus.
P21 Benefits
- P21 benefits center on hippocampal neurogenesis, tau reduction, and preclinical cognitive improvement.
- P21 rescued impaired hippocampal neurogenesis in 3xTg-AD mice fed the compound for 12 months (Kazim et al. 2014)[1]. That includes both proliferation and dendritic maturation of new neurons in the dentate gyrus.
- Tau hyperphosphorylation dropped significantly in the same Alzheimer's model [1], one of the few research compounds with preclinical tau-reduction data outside the pharmaceutical pipeline.
- Normal adult mice (not disease models) showed improved spatial reference memory after P21 treatment (Li et al. 2010, C57BL/6 strain)[3]. That healthy-mouse data is why community users extrapolate beyond Alzheimer's contexts.
- The tetrapeptide crosses the blood-brain barrier after peripheral administration; no special delivery system required. Intranasal dosing offers even more direct CNS access via olfactory and trigeminal pathways.
- Community users consistently report no stimulant-type side effects or tolerance development across cycles, and some describe vivid dreams during weeks 3 to 4 as a possible neurogenesis correlate.
P21: Science vs Community Consensus
Preclinical evidence supports restored hippocampal neurogenesis, reduced tau hyperphosphorylation and better spatial memory in 3xTg-AD and normal adult C57BL/6 mice.
Read the evidence (key study, limitations)
A 2024 study [2] in a CDKL5 deficiency disorder model showed in vitro benefit but failed to replicate neurogenesis or BDNF improvement in vivo: suggesting model-specific and potentially disease-context-dependent effects. Zero human clinical trial data exists.
PMID 25046994: Kazim et al. (2014): 12 months of oral P021 in the diet reduced tau hyperphosphorylation and rescued cognition, neurogenesis and synaptic plasticity in 3xTg-AD mice
All evidence from rodent models. No human trial registered on ClinicalTrials.gov as of October 2026. 2024 negative in vivo result (PMID 39592934) in CDKL5 model raises questions about generalizability across disease contexts. No formal human PK data; half-life is plasma-stability estimate only.
Subtle, cumulative cognitive improvements reported: primarily spatial memory and recall clarity.
Read the reports (what users report 4, common issues 4)
Intranasal route strongly preferred over SC; many users report no perceivable effect from SC at standard doses. Effects not felt acutely; onset requires 2–4 weeks minimum.
- Subtle but consistent memory consolidation improvement, especially spatial recall
- No stimulant-type side effects or tolerance development
- Clean, non-acute mechanism: some users report vivid dreams as a neurogenesis signal
- One of few research compounds with preclinical tau-reduction data
- No acute feel: effects only apparent over weeks, hard to attribute to compound
- Intranasal requires 5–10x more peptide than SC; expensive per cycle (~$18–30/day at 1 mg IN)
- Near-zero human data: all effects extrapolated from rodent models
- SC route frequently reported as ineffective at calculator-listed doses
Science demonstrates neurogenesis and tau reduction in AD rodent models; community reports subtle cognitive improvements in healthy adults: mechanistically plausible (PMID 20600002 used normal adult mice) but not directly comparable. SC dosing tiers align between file and community; intranasal dosing diverges substantially (not in calculator). 2024 negative CDKL5 in vivo result adds nuance: effects may be disease/model context-dependent.
P21 Dosage Guide
Start subcutaneous if you want to test the waters cheaply. But know that a lot of community users gave up on SC at beginner doses and only found the compound useful intranasally.
Reconstitution math for SC: take a 10 mg vial, add 2 mL bacteriostatic water. That gives you 5 mcg per microliter. For the beginner dose (100 mcg), draw 20 units on a U100 insulin syringe. For moderate (300 mcg), draw 60 units. For aggressive (500 mcg), draw 100 units, which is the full syringe. A 5 mg vial with 2 mL BAC water gives 2.5 mcg per microliter; double the units for the same dose.
Intranasal is a different calculation entirely. Reconstitute a 5 mg vial with 1 mL BAC water for 5 mg/mL concentration. Each 0.1 mL spray delivers 500 mcg. At the community top protocol of 1 mg/day, a 5 mg vial lasts five days. A 10 mg vial lasts ten days. That's why intranasal cycles get expensive fast, running $18 to $30 per day at 1 mg.
Don't expect to feel anything for at least two weeks. Track with objective tools: spatial recall tests, word-pair memory tasks, mental rotation exercises. Subjective "feel" is unreliable with this compound.
Cycling Protocol
Cycling recommended due to lack of long-term human safety data. Neurogenic effects are gradual and cumulative: do not expect acute cognitive changes. Some protocols suggest 2-4 weeks off between cycles. Discontinue if side effects emerge.
No long-term human safety data exists. LIF pathway competitive inhibition affects not only hippocampal neurogenesis but also neuroimmune balance (LIF is a pleotropic cytokine with systemic roles). Off-periods allow monitoring for cumulative immunological or neurological effects and avoid unknown risks from continuous LIF pathway modulation. Neurogenic effects appear structural and persistent in animal models: off-cycling does not appear to eliminate achieved neurogenesis.
- Persistent or worsening headache beyond week 2 of a cycle
- Unusual fatigue or immune-like inflammatory symptoms
- Mood destabilization or significant new anxiety
- New focal neurological symptoms (visual, motor, sensory)
Or use the universal Peptide Calculator for any peptide.
P21 Protocols by Goal
Expected: Mild improvement in memory consolidation and spatial recall by weeks 3–4, if SC route is effective for the individual. Many report no discernible effect from SC at beginner dose.
Monitor: Log baseline spatial/recall tasks. Reassess at week 4.
How to Use P21
- 1Step 1
Gather supplies: lyophilized P21 vial, bacteriostatic water, alcohol swabs, insulin syringes (28 to 31 gauge for SC) or a nasal spray atomizer for intranasal. Refrigerate reconstituted solution at 2 to 8 degrees Celsius.
- 2Reconstitute
For SC: add 2 mL bacteriostatic water to a 10 mg vial (equals 5 mcg per microliter). For intranasal: add 1 mL to a 5 mg vial (equals 5 mg/mL, or 500 mcg per 0.1 mL spray).
- 3Step 3
For subcutaneous injection: swab the vial top and injection site with alcohol. Draw your dose (beginner 100 mcg equals 20 units; moderate 300 mcg equals 60 units; aggressive 500 mcg equals 100 units on a U100 syringe with the 10 mg/2 mL reconstitution). Inject into abdominal fat at a 45-degree angle. Rotate injection sites daily.
- 4Step 4
For intranasal administration: transfer reconstituted solution to a nasal spray atomizer. One spray of 0.1 mL delivers 500 mcg at the 5 mg/mL concentration. Administer one to two sprays per nostril as needed for your target dose.
- 5Dose once daily in the morning
No timing relative to meals is required.
- 6Cycle 4 weeks on, 4 weeks off
If using the intranasal intermediate protocol, loading at 500 mcg for weeks 1 to 2 and stepping up to 1000 mcg for weeks 3 to 4 is the community top protocol.
- 7Step 7
Store reconstituted solution refrigerated at 2 to 8 degrees Celsius and use within 4 weeks. Lyophilized powder is stable at room temperature for up to 1 month but refrigeration is recommended regardless.
Alternative Routes
5–10× higher absolute dose than SC: 500 mcg–4 mg/day intranasally vs. 100–500 mcg/day SC
Most community users prefer intranasal. Requires nasal spray atomizer. Reconstitute to 5 mg/mL (5 mg vial + 1 mL BAC water) for practical intranasal volumes: each 0.1 mL spray delivers 500 mcg at this concentration. NOTE: calculator dosing tiers apply only to SC: do not use SC tiers for intranasal dosing.
100–500 mcg/day; matches dosing calculator tiers. At moderate dose (300 mcg SC): 5 mg vial lasts ~16 days, 10 mg vial ~33 days.
Standard abdominal or thigh SC injection. Rotate sites. Li 2010 (PMID 20600002) injected P21 subcutaneously in normal adult mice; the 12-month 3xTg-AD study (PMID 25046994) gave it in the diet. Beginner starting point due to lower cost per day vs. intranasal.
P21 Stacking Protocols
Works With
Complementary dual-mechanism stack: Semax provides rapid BDNF-like effects and acute cognitive enhancement; P21 provides slower, structural hippocampal neurogenesis. Different pathways: Semax via BDNF mimicry/5-HT system; P21 via LIF inhibition. Most commonly recommended stack for P21 in community.
P21 IN 500–1000 mcg + Semax IN 100–300 mcg, both morning
Anxiolytic complement. Selank modulates GABAergic and serotonergic pathways without sedation; P21 promotes neurogenesis. Non-overlapping mechanisms. Used to reduce cognitive anxiety/stress alongside P21's slow neurogenic action.
P21 IN 500–1000 mcg + Selank IN 100–300 mcg, both morning
Both promote hippocampal neurogenesis through different mechanisms: P21 via LIF/BDNF pathway, Dihexa via HGF/Met pathway. Community stacks these for aggressive neurogenesis. No safety data for combination; additive neurogenic stimulus is uncharacterized.
Use sequentially rather than simultaneously until interaction data exists
Broad neurotrophic factor mixture with established clinical use in stroke/neuroprotection. Combined with P21's targeted LIF/BDNF mechanism in neuroprotection research stacks. No formal interaction data.
Avoid
Both P21 (LIF/BDNF pathway) and SSRIs (5-HT1A signaling) promote hippocampal neurogenesis through different mechanisms. Additive neurogenic stimulation is theoretically possible but unstudied. Serotonergic modulation may also interact with LIF pathway downstream signaling. Caution warranted; medical supervision recommended if co-administering.
P21's neurogenic stimulation may theoretically lower seizure threshold. Anti-epileptics alter neuronal excitability in ways that could interact unpredictably with LIF pathway modulation. No data exists.
LIF is a pleotropic cytokine involved in immune regulation. Competitive LIF inhibition by P21 could alter immunosuppressant drug effects in uncharacterized ways.
Estimated Cost
Pricing updated 2026-04-09
P21 Side Effects
No human safety data exists for P21. That sentence needs to land before anything else. Every side effect profile below comes from animal studies and anecdotal community reports from a small user base (roughly 30 to 80 Reddit threads).
Full-length CNTF, the parent protein P21 was derived from, caused weight loss, persistent cough, and antibody formation when tested in human ALS trials. P21 was specifically engineered to avoid those effects by using only four residues instead of the full protein. Whether the modification eliminates all CNTF-associated risks in humans is unknown because no human toxicology study has been performed.
Community-reported side effects: headache is the most common, typically transient and concentrated in the first 3 to 5 days. Mild fatigue during initial dosing. Transient brain fog that usually resolves within a week. Intranasal irritation if using a nasal spray atomizer. None of these have been documented in controlled settings.
The theoretical concerns deserve attention. P21 inhibits LIF signaling, and LIF is a pleiotropic cytokine with roles in immune regulation beyond just neurogenesis. Sustained LIF pathway modulation could theoretically affect neuroimmune balance. Mood destabilization, unusual fatigue, or inflammatory-type symptoms during a cycle may signal immune effects that warrant discontinuation.
Neurogenic stimulation carries its own theoretical risk. Active cancer, especially CNS tumors, is a contraindication; promoting neural progenitor cell proliferation in someone with existing tumor biology could be dangerous. The under-25 population should avoid P21 because brain development is still ongoing.
Pregnancy and breastfeeding: no reproductive toxicology data exists. Autoimmune neurological conditions are contraindicated because LIF pathway modulation may disrupt neuroimmune balance in unpredictable ways. Known hypersensitivity to CNTF-derived compounds is an obvious exclusion.
Drug interactions: both P21 and SSRIs/SNRIs promote hippocampal neurogenesis through different pathways (LIF/BDNF versus 5-HT1A signaling). Combined effects are unstudied. Anti-epileptic medications may interact because neurogenic stimulation could theoretically lower seizure threshold. Immunosuppressants like methotrexate and cyclosporine could behave differently under LIF pathway inhibition.
Stop immediately and consult a physician if you develop persistent headache beyond week 2, new focal neurological symptoms (visual, motor, or sensory changes), significant mood shifts, or signs of immune dysregulation.
Common Issues & Solutions
No acute cognitive effects felt: P21 requires neurogenesis timescale (~4 weeks minimum). Use objective tracking tools (spatial recall tasks, word-pair memory tests) rather than subjective feel to assess efficacy. No response at week 4 via SC may indicate route failure: consider switching to intranasal.
SC route feels ineffective: Community frequently reports SC doses below 300–500 mcg produce no perceivable benefit. The intranasal route at 500–1000 mcg is reported as substantially more reliable. Consider route switch if 2+ weeks of SC produce no response.
Dosing confusion between SC and intranasal: The calculator tiers (100/300/500 mcg) apply to subcutaneous administration only. Intranasal requires 5–10× higher absolute doses (500 mcg–4 mg/day). Do not apply SC calculator tiers to intranasal administration.
Off-cycle timing uncertainty: The notes field says "2–4 weeks off" but the cycling protocol sets 4 weeks. Use the conservative 4-week off period given unknown long-term LIF pathway effects: the 2-week interval is community experimentation, not clinically validated.
Stacking P21 and Dihexa together: Both compounds are neurogenic via different pathways but have zero combination safety data. Establish response to each compound separately in sequential cycles before considering a combined cycle.
Ask AI about this page
Ask AI for a second opinion on P21 dosing and side effects
Contraindications
- Pregnancy or breastfeeding: no reproductive toxicology data exists
- Individuals under 25: brain development still ongoing
- Active cancer or history of CNS tumors: neurogenic stimulation may carry theoretical risk
- Known hypersensitivity to CNTF-derived compounds
- Autoimmune neurological conditions: LIF pathway modulation may affect neuroimmune balance
Drug Interactions
- Immunosuppressants (e.g., methotrexate, cyclosporine): LIF pathway involvement in immune regulation may alter drug effects
- Antidepressants (SSRIs, SNRIs): both P21 and serotonergic drugs affect hippocampal neurogenesis; combined effects are unstudied
- Anti-epileptic medications: neurogenic stimulation may theoretically lower seizure threshold; no data available
- Other nootropic peptides (Semax, Selank, Dihexa): no interaction data exists; use caution when stacking
- LIF is a pleotropic cytokine involved in immune regulation. Competitive LIF inhibition by P21 could alter immunosuppressant drug effects in uncharacterized ways.
Product Quality
Research-only compound with no FDA-regulated manufacturing standard. Gray-market research products vary in analytical rigor. No standardized injectable-grade formulation exists. Pre-made intranasal spray products have variable excipient quality and sterility assurance.
- CoA benchmark: HPLC purity ≥98% with mass spectrometry (MS) confirmation
- Independent third-party lab verification is stronger evidence than an in-house CoA alone
- For intranasal use, confirm excipient list: bacteriostatic water or preserved saline only; avoid propylene glycol or DMSO in nasal preparations
- Lyophilized powder (self-reconstitute) is generally safer than unverified pre-made nasal spray
- Storage: room-temperature 1-month claim in some product listings is more permissive than standard peptide guidance: refrigerate lyophilized powder regardless; never leave reconstituted solution unrefrigerated
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Cognitive function self-assessment | Baseline before cycle; week 2; week 4; 2 weeks post-cycle | No specific target: looking for directional improvement from personal baseline |
| Mood and anxiety tracking | Weekly throughout cycle | Not listed |
| Neurological symptom log | Daily during weeks 1–2, then weekly | Not listed |
P21 has no acute subjective signal. Objective tasks (spatial recall, word-pair memory, mental rotation) are the only reliable way to detect benefit or worsening.
LIF pathway modulation affects neuroimmune balance. Immune dysregulation can present as mood shifts, unusual fatigue, or anxiety: early warning signs for discontinuation.
Absolute contraindication for CNS tumors and autoimmune neurological conditions. Any new headache pattern, visual changes, or focal neurological signs warrants immediate discontinuation.
P21 Before and After
No significant cognitive changes expected. Neurogenic processes are gradual. Any perceived effects during this window may be placebo. Animal studies show early increases in BDNF expression.
In mouse models, measurable increases in hippocampal neurogenesis and dendritic maturation occur within this window. Anecdotal reports describe subtle improvements in focus and memory recall.
No animal study places a peak in this window. Recommended cycle endpoint. Human translatability is unknown.
What to Expect
Weeks 1 to 2 (Silent phase): Don't expect to feel anything. Animal data shows early BDNF upregulation and neural progenitor cell proliferation starting in the dentate gyrus subgranular zone, but no behavioral changes appeared in rodent studies at this stage. Community users confirm: any perceived improvement this early is likely placebo. Some people report mild headache or transient brain fog in the first 3 to 5 days, plus minor intranasal irritation if using spray.
Weeks 2 to 4 (Neurogenesis acceleration): Animal models show measurable increases in hippocampal neurogenesis and dendritic maturation. Normal adult mice showed improved spatial reference memory after peripheral dosing (Li et al. 2010)[3]. Community users describe subtle improvements in memory consolidation and spatial recall. Some report vivid dreams, which gets interpreted as a neurogenesis signal. Verbal recall and language retrieval sometimes improve. Side effects are generally absent; occasional mild fatigue gets mentioned.
Weeks 4 to 6 (Cycle endpoint): The 3xTg-AD tau and neurogenesis results come from 12 months of dietary dosing [1], so no animal data places a peak in this window. That study also found rescued synaptic plasticity. Weeks 4 to 6 mark the recommended cycle endpoint. Community users who complete a full cycle describe consistent but subtle gains, mostly in multi-step memory tasks, spatial navigation, and recall precision. No side effects typically reported at this stage.
Post-cycle weeks 7 to 10 (Off-cycle monitoring): Community users generally perceive cognitive improvements as retained during off-cycle. Some report gradual return to baseline by weeks 8 to 10 off-cycle. The 4-week off period is recommended given unknown long-term LIF pathway effects.
Detailed Timeline: Science vs Community
Early BDNF upregulation and neural progenitor cell proliferation in dentate gyrus subgranular zone (animal data). No measurable behavioral changes at this stage in rodent studies.
No perceivable effects. Any improvement at this stage is likely placebo. Some users report mild headache or transient brain fog in first 3–5 days.
Measurable increases in hippocampal neurogenesis and dendritic maturation in animal models. Improved spatial reference memory in C57BL/6 normal adult mice after subcutaneous dosing (PMID 20600002).
Subtle improvements in memory consolidation and spatial recall. Some users report vivid dreams as a neurogenesis correlate. Verbal recall and language retrieval sometimes noted.
Tau reduction and rescued neurogenesis in 3xTg-AD mice after 12 months of dietary P021 (PMID 25046994); no study maps these effects to weeks 4 to 6. The same study found rescued synaptic plasticity. Human translatability timeline is unknown.
Most users complete cycle here. Improvements subtle but consistent: most notable in multi-step memory tasks, spatial navigation, and recall precision.
Animal studies show sustained neurogenic benefits persisting well beyond dosing period (18-month follow-up in some models). Reversal timeline in humans unknown.
Cognitive improvements generally perceived as retained during off-cycle. Some users report gradual return to baseline by week 8–10 off-cycle.
Pharmacokinetics
Source: No measured half-life in any species. Lab tests found P21 over 90% intact in gastric juice and over 97% in intestinal fluid at 37°C. That shows GI stability, not a plasma half-life.
Is P21 Legal?
P21 is classified as a research compound. It has no FDA approval and no Orphan Drug Designation. No Phase I trial of P21 is registered on ClinicalTrials.gov as of October 2026.
P21 is not scheduled or controlled in the United States. It is sold on the gray market as a research chemical under "for research purposes only" labeling. No compounding pharmacy formulation exists; there is no USP monograph or injectable-grade manufacturing standard.
Athletes should note that while P21 is not explicitly listed on the World Anti-Doping Agency (WADA) prohibited list by name, the S2 category (peptide hormones and growth factors) and S0 category (unapproved substances) could apply. Check current WADA status before competing.
This content is for educational and research reference only. P21 is not approved for human use. Consult a qualified healthcare provider before using any research compound.
Evidence grade: No human studies found (Peptide Evidence Gap, October 2026)
Who Should Consider P21
- Researchers investigating CNTF/LIF pathway modulation and hippocampal neurogenesis
- Individuals exploring experimental nootropics under medical supervision
- Adults studying preclinical approaches to age-related cognitive decline
- Those researching tau pathology and Alzheimer's disease interventions
Related Peptides
What Changed for P21
Peptide Schedule Research TeamReviewed Apr 7, 20264 Citations
References
- [1]Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease (Kazim et al., Neurobiol Dis 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in CDKL5 deficiency disorder (Mottolese et al., J Neurodev Disord 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice (Li et al., FEBS Lett 2010) (opens in a new tab)PubMed (opens in a new tab)PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is P21?
Emerging. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 30–80. Community mentions on Reddit: ~30–80 threads across r/nootropics, r/peptides. Open r/nootropics (opens in a new tab).
15 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Low search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.